Loading IPO status…
| Industry | Health Tech |
| Stage | Growth Stage |
| IPO Status | Pre-IPO |
| Valuation | $2B+ |
| Total Funding | $200M |
| Headquarters | United States |
| IPO Readiness Score | 60/100 |
| Founded | 2020 |
Track eMed IPO status, valuation updates, and S-1 filing milestones on TechStackIPO.
eMed has an IPO readiness score of 60/100 on TechStackIPO. A moderate readiness score suggests the company may be 2–4 years from IPO.
eMed's last known private valuation is $2B+. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.